Search

Ex-Cubist CEO Bonney Emerges at Kaleido, Flagship's Latest Microbiome Startup

EX-CUBIST CEO BONNEY EMERGES AT KALEIDO, FLAGSHIP'S LATEST MICROBIOME STARTUP

Flagship Pioneering has been as active as any venture firm at funneling its investment dollars into microbiome drug developers. It's...

 
 
 
After Biogen Deal Fizzles, Rodin Bags $27M And Heads To First Trial

AFTER BIOGEN DEAL FIZZLES, RODIN BAGS $27M AND HEADS TO FIRST TRIAL

An option-to-buy deal, when one company agrees to buy another on prearranged terms after a series of milestones are met, doesn't always...

 
 
 
Immunotherapy Safety Worries Halt Celgene Myeloma Study, Slow 5 Others

IMMUNOTHERAPY SAFETY WORRIES HALT CELGENE MYELOMA STUDY, SLOW 5 OTHERS

Amid growing concerns about the safety of a new class of cancer immunotherapy drugs when combined with other therapies to treat blood...

Celgene Broadens Forma Deal, Adding $195M More for Drug R&D

CELGENE BROADENS FORMA DEAL, ADDING $195M MORE FOR DRUG R&D

Celgene and Forma Therapeutics are expanding their already extensive relationship. The Summit, NJ-based drugmaker has exercised a $195...

 
 
 
 
 
 
 
 
 
Invenra Signs On With Merck in Antibody Discovery Partnership

INVENRA SIGNS ON WITH MERCK IN ANTIBODY DISCOVERY PARTNERSHIP

Invenra has had success developing therapeutic antibodies for its own drug research, and for the research of others. Now the Madison,...

 
 
 
Eli Lilly Pays Nektar $150M Up Front For Autoimmune Drug Rights

ELI LILLY PAYS NEKTAR $150M UP FRONT FOR AUTOIMMUNE DRUG RIGHTS

Nektar Therapeutics has been buoyed of late by the progress of a potential pain drug, but another, much earlier program has caught...

 
 
 
 
 
 

CELGENE TOUTS OZANIMOD MS DATA, BUT DISABILITY BENEFIT WEAK OVER RIVAL DRUG

Celgene has posted some new late-stage data from its second pivotal test in multiple sclerosis for its $7.2 billion oral candidate...

Ex-Sarepta CEO Garabedian Returns to Run Bio Accelerator Xontogeny

EX-SAREPTA CEO GARABEDIAN RETURNS TO RUN BIO ACCELERATOR XONTOGENY

Chris Garabedian, a veteran biotech executive who helped turn Sarepeta Therapeutics around before his controversial exit in 2015, has...

 
 
 

EX-MERCK R&D EXEC ROBERT PLENGE JUMPS SHIP TO CELGENE

Ex-Merck R&D exec Robert Plenge jumps ship to Celgene badams Mon, 05/01/2017 - 04:36

Celgene's quarterly profits beat with help from sales of its flagship cancer drug

CELGENE'S QUARTERLY PROFITS BEAT WITH HELP FROM SALES OF ITS FLAGSHIP CANCER DRUG

Thomson Reuters April 27 - U.S. biotechnology company Celgene Corp reported a better-than-expected profit on Thursday, helped by demand...